Umberto Malapelle

TL;DR: The International Association for the Study of Lung Cancer (IASLC) liquid biopsy statement as mentioned in this paper revisited the role of liquid-biopsy in therapeutic decision-making in a recent workshop in October 2020 and the question of "plasma first" versus "tissue first" approach toward molecular testing for advanced NSCLC.

TL;DR: The Roche cobas® EGFR mutation test v2, based on real time RT-PCR, is a reliable option for testing EGFR mutations in clinical practice, either using tissue-derived DNA or plasma-derived cfDNA, and will be valuable for laboratories with whose purpose is purely diagnostic and lacking high-throughput technologies.

TL;DR: It is found that the lack of CBX7 protein expression in human lung carcinomas correlated with CCNE1 overexpression, which suggests that CBx7 is a tumor suppressor and that its loss plays a key role in the pathogenesis of cancer.

TL;DR: A panel to use in ultra-deep sequencing to identify mutated alleles in cfDNA involved in non-small-cell lung cancer, gastrointestinal stromal tumour, colorectal carcinoma and melanoma and a feasible NGS panel for cfDNA analysis in clinical practice is developed.

TL;DR: The role of the Hh pathway in mediating resistance to anti-EGFR-TKIs through the induction of EMT is supported and suggests new opportunities to design new treatment strategies in lung cancer.